PARD6A

Across TCGA pan-cancer cohorts, PARD6A Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PARD6A data layer compared with 27 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher PARD6A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PARD6A expression acts as an unfavorable survival marker.

BRCA, STAD, and LUSC are the cancer types where PARD6A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.583	0.924	<.001	32	view →
STAD	OS	Median	II,III,IV	0.183	0.660	.009	12	view →
LUSC	OS	Median	All	0.078	0.776	<.001	12	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PARD6A–BRCA (OS)

Open the BRCA breakdown →